Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
UPDATE: 09/23/13
Updated the current share prices on the Stock Watchlist.
PURCHASE: IGXT
I purchased 1,000 shares of IGXT at .57 today.
Yes the stock is an OTC stock but it has a PDUFA date of February 3, 2013. Also the S-1 should be closed within the next week.
PURCHASE: ETRM
I purchased ETRM at a Cost Basis of $1.20 on 09/16/13.
Should be hearing about a possible ADCOM in the coming weeks.
PURCHASE: PBMD
Purchased PBMD @ 2.345 for a combined Cost Basis of 2.40.
I believe the stock should turn north soon. Result from CAN-103 is to be released on October 01, 2013.
NEWS: NVAX - Currently Holding (updated)
NVAX - Currently Holding
Link for Novavax, Inc. Wedbush 2013 Life Sciences Management Access presentation on August 13, 2013 by president and CEO Stanley C. Erck.
NVAX Wedbush Presentation
NVAX - Currently Holding
Novavax, Inc. has a very interesting week.
Beginning on Wednesday, September 11, 2013 NVAX will present at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Denver, Colorado the session, entitled “RSV F Protein Vaccine Is Well-Tolerated and Immunogenic in Elders,” will present data from the company’s recently completed Phase 1 clinical trial of its RSV vaccine candidate in healthy elderly adults. Also, on the 11th “Passive Immunization with RSV F Vaccine-Induced Polyclonal Antibodies Protect Cotton Rats from RSV A Challenge" will be presented, both sessions are scheduled to be presented from 11:00AM - 01:00PM.
Then on Thursday, September 12, 2013 President and CEO of NVAX Stanley C. Erck will present at the Stifel Nicolaus Healthcare Conference 2013 in Boston, Massachusetts @ 09:45AM.
Links for more information on the presentations.
Novavax, Inc. Events
UPDATE: iBox - 09/09/13
Updated the Stock Watchlist with current 10-day moving average volumes and prices.
NEWS: CHTP
CHTP price target raised to $4.00 from $3.50 with a "buy" rating at Ladenburg Thalmann.
NEWS: NSTG, CGIX, TRGT, CEMI
NSTG
New Workflow to Provide Scientists with Tools That Enable Single Cell Analysis for Oncology, Immunology and Stem Cell Research
CGIX
Cancer Genetics, Inc. [CGIX] to Ring The NASDAQ Stock Market Opening Bell
Cancer Genetics Announces Exercise of Underwriters' Over-Allotment Option
TRGT
Targacept to Present at the Stifel Healthcare Conference 2013
CEMI
Form 8-K for CHEMBIO DIAGNOSTICS, INC.
UPDATE: 09/05/13
Updated the Stock Watchlist Current Prices
NEWS: APPY, RIGL
APPY
APPY Income Statement
Venaxis to Present at Three Upcoming Investor Conferences
RIGL
Rigel To Focus On ITP, DLE And Dry Eye
INFO: BioTech
Drug firms and cancer: Lucrative lifesavers
PURCHASE: NVAX
Added to a position in NVAX this morning at a Cost Basis of 3.30 a share for a combined Cost Basis of 3.25 a share for total NVAX holdings.
SOLD: MSTX
I sold the remaining MSTX shares I had at .4201 for a slight loss.
INFO: BioTech
It's No Accident That Drugs Are Expensive
UPDATE: iBox - 09/01/13
Updated the portfolio balance for America, also updated the Stock Watchlist with current 10-day moving average volume and prices.
PURCHASE: NVAX
I bought NVAX at a Cost Basis of 3.23. The company has a last minute presentation scheduled for September 12, 2013. The company must have some important information to release, so the stock should appreciate until then.
Genocea Biosciences Selected To Present Late-Breaking Oral Presentation At ICAAC 2013
ZLCS - Currently Holding
The stock is moving up again today; trading at .711 or up .038 (5.65%) from yesterday.
The volume is also over half of the 10-day moving average of volume in just 20 minutes of trading.
ZLCS - Currently Holding
The stock had a good day, finishing up .0329 or 5.14% on nearly two times the 10-day moving average of volume.
It will be interesting to see where the stock ends up tomorrow before the three-day Labor Day weekend.
UPDATE: iBox - 08/29/13
Updated the Stock Watchlist current prices
ZLCS - Currently Holding
The volume has increase today. The volume is around the 10-day moving volume average with 4 hours left in trading. The share price is currently up .0399 for today and .03 since my purchase yesterday at a Cost Basis of .65.
PRUCHASE: PBMD
Purchased PBMD at a Cost Basis of 2.51. The company has an October 1, 2013 catalyst. The company just did a $60mm shelf.
PURCHASE: ZLCS
I purchased ZLCS at a Cost Basis of .65
The company will release information on Z160 towards the end of October.
The company also may do a reverse split if the stock price does not rise above $1 for ten days straight before October 21 to comply with the NASDAQ $1 minimum bid price. The stockholders have approved both a 1 for 5 and a 1 for 10 split.
Here is a Seeking Alpha article for quick information on ZLCS.
For Zalicus, Z160 Data In October Could Be Huge
UPDATE: iBox - 08/28/13 Afternoon
Updated the Stock Watchlist current prices
SOLD: MSTX
Sold 2/3 for a 2.91% gain. Holding a core to see what happens in the coming days.
UPDATE: iBox - 08/28/13
Updated the Stock Watchlist current prices
NEWS: AKRX, HITK, OREX, SRDX, CNDO, ABBV, QCOR
AKRX, HITK
Akorn Agrees to Purchase Hi-Tech Pharmacal for $640 Million
OREX
Orexigen Therapeutics Prepares for the Light Study Interim Analysis Based on Direction from Data Monitoring Committee
SRDX
SurModics to Present at CL King’s Best Ideas Conference
CNDO
Coronado Biosciences to Participate in Citi's 8th Annual Biotech Conference
ABBV
AbbVie to Present at Morgan Stanley Global Healthcare Conference
QCOR
Questcor Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference
NEWS: CPRX
CPRX - the stock is rocketing today, missed out on this one as I sold it for a loss last week.
Catalyst Pharmaceutical Partners Receives Breakthrough Therapy Designation From FDA for Firdapse(TM) for the Treatment of LEMS
MSTX - Currently Holding
MSTX had an interesting day. The stock finished up .015 or 3.57% on 1,766,131 in volume; close to three times the 10-day moving average. Sometimes where there is an increase in volume there could be an increase in share price.
UPDATE: iBox - 08/26/13
Updated the Stock Watchlist current prices.
CLSN - The company will announce HEAT study results 09/14/13. The stock price could have a run up to the announcement. I will watch this one and look at a possible entry.
Celsion Announces Official ThermoDox® HEAT Study Results to be presented at the International Liver Cancer Association (ILCA) 2013 Annual Conference in Washington, D.C. on September 14, 2013
MSTX - Currently holding
The stock is looking good today; it is up 6.88% to .4489 with over 1,300,000 shares traded - far above the 668,523 10-day moving average of volume. There is still over 3 1/2 hours left in trading so it could be telling where the stock ends up at 4PM.
***Edit
The RSI on the hourly chart has just dropped below overbought and the MACD line has crossed over the signal to the positive, meaning appreciation could be in the works.
The RSI on the daily is a little over half way between the overbought and oversold lines - meaning accumulation is happening but not at a rate to be worried about; and, the MACD line is about to cross the signal if this happens the stock might move up even more.
NEWS: CXM, NVO, FCSC
CXM
Cardium's LifeAgain Announces Commercialization Agreement With AgencyONE Based On Advanced Medical Data Analytics Platform Technology
NVO
On 8 August 2013, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 14.0 billion to be executed during a 12-month period beginning 31 January 2013.
Company Announcement No 57 2013: http://hugin.info/2013/R/1724840/575019.pdf
FCSC
Fibrocell Science Appoints Greg Weaver Chief Financial Officer, Senior Vice President, Treasurer and Corporate Secretary
NEWS: OGEN, NEPT, HEB, PTCT, LIFE, Q
OGEN
Oragenics Collaboration Demonstrates Initial Success in the Second Phase of Lantibiotics Project
NEPT
Neptune Receives Additional $5 Million Insurance Payment
HEB
Hemispherx Announces Biosecurity Program to Potentially Reduce Pandemic Influenza Threat
PTCT
New Evidence Published in Muscle and Nerve on Measuring 6-Minute Walk Distance in Duchenne Muscular Dystrophy
LIFE
Life Technologies Expands Food Testing Portfolio to Global Brewing and Beverage Industry
Q
Quintiles Infosario Receives Computerworld Data+ Editor’s Choice Award
NEWS: RIGL
RIGL
Rigel's R343 Did Not Meet Primary Endpoint in Asthma Study
NEWS: CGEN, CBRX, AMRN, RGDX, ADHD
CGEN
Compugen Establishes Scientific Advisory Board to Guide Pipeline Program Development
CBRX
Columbia Laboratories regains compliance with Nasdaq
AMRN
Amarin Announces Submission of Supplemental New Drug Application for Novasep as Fourth Vascepa(R) Active Pharmaceutical Ingredient Supplier
RGDX
Response Genetics, Inc. Acquires Proprietary FDA-Cleared and Medicare-Reimbursed Test and All Associated Assets for Difficult to Diagnose Solid Tumors
ADHD
Alcobra Enrolls First Patient in Comparative Study of Executive Function Benefits in Patients With PI-ADHD
Update: iBox
I just updated the iBox with current info. I plan on doing this every weekend, to keep the information up to date.
NEWS: AMGN ONXX
AMGN ONXX
Amgen Strikes $10.4 Billion Deal for Onyx
MSTX - great volume today - 718,757 shares traded compared to the 10 day average of 652,198. And there's still 4 1/2 hours left in trading.
Looks like CPRX will fall today with the warrants being exercised
NEWS: CPRX
Catalyst receives $1.07M from exercise of warrants • 8:59 AM
Catalyst Pharmaceutical (CPRX) has received $1.07M from the exercise of stock warrants to buy 1.03M shares.
The company issued the warrants in its IPO in May last year.
Catalyst doesn't appear to have provided any further details in the 8-K disclosing the news.
The amount received indicates a price of $1.04 a share vs yesterday's close of $1.31.
Followers
|
1
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
66
|
Created
|
08/15/13
|
Type
|
Premium
|
Moderators |
TICKER | Reason for Purchase | Cost Basis | Purchase Date | Purchase Average Volume (10 day) | Sell Price | Sell Date | Gain / Loss (%) |
---|---|---|---|---|---|---|---|
MSTX | Catalyst Play Through 2013 | .42189 | 08/15/13 | 358,019 | 2/3 @ .431 1/3@.4201 | 08/28/13 09/03/13 | 2.91 .02 = 1.93 |
ZLCS | October readout of data / possible reverse split | .65 | 08/28/13 | 1,490,229 | .7114 | 08/30/13 | 7.19 |
NVAX | September 11, 2013 presentation @ICAA. September 12, 2013 presentaion @ Stifel Nicolaus September 24, 2013 annual "Analyst Meeting." $11 price target from Lazard. | 3.23 3.30 = 3.25 | 08/30/13 09/03/13 | 4,173,193 | 3.36 | 09/12/13 | 2.36 |
ETRM | Should be hearing about a possible ADCOM soon. | 1.20 | 09/16/13 | 700,000 | 1.23 | 09/23/13 | 2.5 |
Ticker | Reason for Purchase | Cost Basis | Purchase Date | Purchase Average Volume (10-day) | Sell Price | Sell Date | Gain / Loss (%) |
---|---|---|---|---|---|---|---|
TICKER | Reasons | First Observed Date | First Observed Price | Current Price* | First Observed Average Volume (10 day) | Current Average Volume (10 day) | Notes: |
---|---|---|---|---|---|---|---|
Label | Description |
---|---|
Info | Article and / or information on the topic listed |
News | News release on the ticker(s) mention |
Purchase | Bought a position in mention ticker |
Sold | Sold out of a postition in mention ticker |
Ticker | Update(s) and Insight(s) on stated ticker |
Update | Updates made to the iBox |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |